复宏汉霖产品成为全球首个胃癌围术期以免疫单药取代术后辅助化疗的治疗方案

Core Insights - The company, Fuhong Hanlin (2696.HK), announced a significant breakthrough in gastric cancer treatment with its self-developed PD-1 inhibitor, H drug (sulfuril monoclonal antibody), achieving the primary endpoint of event-free survival in the phase III clinical study (ASTRUM-006) [1] Group 1 - The ASTRUM-006 study represents the first global instance of using an immune monotherapy to replace postoperative adjuvant chemotherapy in perioperative gastric cancer treatment [1] - The mid-term analysis of the clinical study was reported on October 9, indicating a successful outcome [1] - This development marks a major advancement in the field of gastric cancer therapy [1]